Role of Ultrasound-Based Therapies in Cardiovascular Diseases
Author: Amit Bansal1,2, Bernard Bulwer3, Ricarda von Krüchten4,5, Jagkirat Singh6, Rajan Rehan7, Ata Doost8
Affiliation:
1 Bergen COVID-19 Research group and Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.
2 Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
3 Cardiovascular Imaging Core Laboratory, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston.
4 Stanford University, School of Medicine, Stanford, United States.
5 University of Freiburg, Medical Center, Freiburg, Germany.
6 Department of Neurology, Creighton University, School of Medicine, Omaha.
7 University of Sydney Medical School, Sydney, Australia.
8 Macquarie University, Faculty of Medicine and Health Sciences and Macquarie University Hospital, Sydney, Australia.
Conference/Journal: Struct Heart
Date published: 2024 Jul 16
Other:
Volume ID: 9 , Issue ID: 2 , Pages: 100349 , Special Notes: doi: 10.1016/j.shj.2024.100349. , Word Count: 227
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality globally, placing an immense burden on health care costs worldwide. The emergence of therapeutic ultrasound-based therapies in the CVD management represents a promising innovative strategy beyond current established approaches. This paper explores three distinct modalities of ultrasound-based therapies-high-intensity focused ultrasound, extracorporeal shock wave therapy, and low-intensity pulsed ultrasound-each characterized by unique acoustic parameters and mechanisms of action tailored to specific therapeutic outcomes. High-intensity focused ultrasound was shown to be beneficial as an adjunct in the treatment of myocardial infarction and arrhythmias. It has also been investigated for the in vivo treatment of resistant hypertension, symptomatic aortic valve stenosis, arterial stenosis, tumors, hypertrophic cardiomyopathy, and external cardiac pacing. Extracorporeal shock wave therapy was shown to be beneficial in the treatment of chronic refractory angina pectoris, while low-intensity pulsed ultrasound was shown to be beneficial in dissolving blood clots and improving blood flow in the treatment of acute pulmonary embolism, despite its association with an increased risk of bleeding. Ultrasound-based therapies are, therefore, a potential adjunct and comparatively safe adjuncts for managing challenging CVD cases. Further investigations are essential to validate their long-term effectiveness and safety, particularly for high-risk individuals susceptible to postprocedural complications.
Keywords: Cardiovascular disease; ECSWT; Extracorporeal cardiac shock wave therapy; HIFU; High-intensity focused ultrasound; LIU; Low-intensity ultrasound; Therapeutic ultrasound.
PMID: 40124079 PMCID: PMC11925036 DOI: 10.1016/j.shj.2024.100349
BACK
